000 | 01929 a2200529 4500 | ||
---|---|---|---|
005 | 20250517000212.0 | ||
264 | 0 | _c20150615 | |
008 | 201506s 0 0 eng d | ||
022 | _a1549-4713 | ||
024 | 7 |
_a10.1016/j.ophtha.2014.08.031 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aCampochiaro, Peter A | |
245 | 0 | 0 |
_aIntravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. _h[electronic resource] |
260 |
_bOphthalmology _cMar 2015 |
||
300 |
_a538-44 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aDouble-Blind Method |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aIntravitreal Injections |
650 | 0 | 4 | _aLaser Coagulation |
650 | 0 | 4 |
_aMacular Edema _xdrug therapy |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aReceptors, Vascular Endothelial Growth Factor _xadverse effects |
650 | 0 | 4 |
_aRecombinant Fusion Proteins _xadverse effects |
650 | 0 | 4 |
_aRetinal Vein Occlusion _xcomplications |
650 | 0 | 4 | _aSickness Impact Profile |
650 | 0 | 4 | _aSurveys and Questionnaires |
650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
650 | 0 | 4 |
_aVisual Acuity _xphysiology |
700 | 1 | _aClark, W Lloyd | |
700 | 1 | _aBoyer, David S | |
700 | 1 | _aHeier, Jeffrey S | |
700 | 1 | _aBrown, David M | |
700 | 1 | _aVitti, Robert | |
700 | 1 | _aKazmi, Husain | |
700 | 1 | _aBerliner, Alyson J | |
700 | 1 | _aErickson, Kristine | |
700 | 1 | _aChu, Karen W | |
700 | 1 | _aSoo, Yuhwen | |
700 | 1 | _aCheng, Yenchieh | |
700 | 1 | _aHaller, Julia A | |
773 | 0 |
_tOphthalmology _gvol. 122 _gno. 3 _gp. 538-44 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ophtha.2014.08.031 _zAvailable from publisher's website |
999 |
_c24278801 _d24278801 |